References
- Fisher B, Constantino J P, Redmond C K, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel project (NSABP) B-14. J Natl Cancer Inst 1994; 86: 527–537
- Killackey M A, Hakes T B, Pierce V K. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 1985; 69: 237–238
- Fornander T, Rutqvist L E, Cedermark B, et al. Adjuvant tarnoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989; 1: 117–120
- Malfetano J H. Tamoxifen-associated endometrial carcinoma in postmenopausal breast cancer patients. Gynecol Oncol 1990; 39: 82–84
- Magriples U, Naftolin F, Schwartz P E, et al. High grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 1993; 11: 485–490
- Barakat R R, Wong G, Curtin J P, et al. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a high incidence of adverse histologic features. Gynecol Oncol 1994; 55: 164–168
- Silva E G, Tornos C., Pollen S., Mitchell M. Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: the effects of tamoxifen. Int J Gynecol Path 1994; 13: 248–258
- Ragaz J, Coldman A. Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes. J Clin Oncol 1998; 16: 2018–2024
- Beliere M, Charles A, Galant C, et al. Uterine side effects of tamoxifen: a need for systematic pretreatment screening. Obstet Gynecol 1998; 91: 40–44
- Gal D, Kopel S, Bashevkin M, et al. Oncogenic potential of tamoxifen on endometria of postmenopausal women with breast cancer—preliminary report. Gynecol Oncol 1991; 42: 120–123
- Neven P, De Muylder X, Van Belle Y, et al. Tamoxifen and the uterus and endometrium. Lancet 1989; 1: 375–376
- De Muylder X, Neven P, De Somer M, et al. Endometrial lesions in patients undergoing tamoxifen therapy. Int J Gynecol Obstet 1991; 36: 127–130
- Mignotte H., Lasset C, Bonadona V, et al. latrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC). Int J Cancer 1998; 76: 325–330
- Goldstein S R. Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol 1994; 170: 447–451
- Goldstein S R. Use of ultrasonohysterography for triage of perimenopausal patients with unexplained uterine bleeding. Am J Obstet Gynecol 1994; 170: 565–570
- Widrich T, Bradley L D, Mitchinson A R, et al. Comparison of saline infusion sonography with office hysteroscopy for the evaluation of the endometrium. Am J Obstet Gynecol 1996; 174: 1327–1334
- Weber A M, Belinson J L, Bradley L D, et al. Vaginal ultrasonography versus endometrial biopsy in women with postmenopausal bleeding. Am J Obstet Gynecol 1997; 177: 924–929
- O'Connell L P, Fries M H, Zeringue E, et al. Triage of abnormal postmenopausal bleeding: a comparison of endometrial biopsy and transvaginal sonohysterography versus fractional curettage with hysteroscopy. Am J Obstet Gynecol 1998; 178: 956–961
- Stovall T G, Photopulos G J, Poston W M, et al. Pipelle endometrial sampling in patients with known endometrial carcinoma. Obstet Gynecol 1991; 77: 954–956
- Eddowes H A, Read M D, Codling B W. Pipelle: a more acceptable technique for outpatient endometrial biopsy. Br J Obstet Gynaecol 1990; 97: 961–962
- Guido R S, Kanbour-Shakir A, Rulin M C, et al. Pipelle endometrial sampling: sensitivity in the detection of endometrial cancer. J Reprod Med 1995; 40: 553–555
- Van den Bosch T, Vandendael A, Van Schoubroeck D, et al. Combining vaginal ultrasonography and office endometrial sampling in the diagnosis of endometrial disease in postmenopausal women. Obstet Gynecol 1995; 85: 349–352